Conversation with Albert Bourla, CEO of Pfizer | Davos | #WEF22

TL;DR

Pfizer CEO, Dr. Albert Bourla, announces that the company will offer patent-protected medicines, including vaccines, to the 45 poorest countries in the world at cost, with the commitment to provide new medicines to these countries each year.

Transcript

good afternoon i have the great pleasure to start a dialogue with one of the chief executives probably most in the news last year and also dr willow you made you made today a very groundbreaking announcement we would certainly come back but i have a pleasure to introduce dr alberto la who is since 2019 just before the kobe crisis broke out you were... Read More

Key Insights

• 💊 Pfizer's donation of patent-protected medicines to the 45 poorest countries demonstrates the company's commitment to improving global healthcare and making medicines more accessible.
• 🔒 The initiative also highlights the importance of public-private cooperation, with Pfizer partnering with organizations, governments, and other stakeholders to address healthcare challenges.
• ♋ The mRNA technology used in Pfizer's COVID-19 vaccine has great potential for future applications in areas like cancer treatment and gene editing.
• 👨‍🔬 The success of the mRNA vaccines has emphasized the need for continued research and development in this field.
• 🎮 Compliance and public trust are crucial in controlling the pandemic and achieving a return to normalcy.
• 🔨 Vaccination remains a vital tool in preventing the spread of infectious diseases and protecting individuals and communities.
• 🏪 Future efforts should focus on improving vaccine convenience, such as developing vaccines with longer durations of efficacy and combining different vaccines for multiple diseases.

Questions & Answers

Q: Which countries will benefit from Pfizer's donation of patent-protected medicines?

The donation will be offered to the 45 poorest countries, which have a total population of 1.2 billion people. These countries are defined based on the World Bank's low-income classification, with some exceptions for countries that have graduated to a higher income level within the last 10 years.

Q: Will Pfizer help these countries develop their own production capabilities?

Pfizer will work with selected countries, such as Rwanda, Malawi, Uganda, Ghana, and Senegal, to address logistical and infrastructure challenges. The company will provide not only medicines but also on-the-ground support to ensure effective distribution and utilization.

Q: How will Pfizer ensure affordability for the donated medicines?

The company defines the cost strictly based on manufacturing and minimal shipment expenses, excluding research and development costs. By eliminating unnecessary expenses, Pfizer can offer the medicines at a lower cost.

Q: Will Pfizer collaborate with other organizations and foundations?

Yes, Pfizer is open to partnering with organizations like the World Health Organization, the Bill & Melinda Gates Foundation, the Carter Foundation, and non-governmental organizations to enhance the impact of this initiative. The goal is to leverage resources and expertise to make a significant difference in global healthcare.

Summary & Key Takeaways

• Pfizer will offer patent-protected medicines to the 45 poorest countries at cost, benefiting 1.2 billion people.

• The company will continuously update its medicine portfolio for these countries with new discoveries and provide support on the ground to address healthcare challenges.

• Pfizer is partnering with organizations and governments to ensure the success of this initiative, and is calling on other stakeholders to join in.